Next |
home / stock / ogen / ogen message board
Subject | By | Source | When |
---|---|---|---|
Maybe not. :) | retired early | investorshub | 03/01/2023 6:46:26 PM |
Don't madder they will short it down to nothing | Nathan123456 | investorshub | 12/22/2022 10:32:36 PM |
Surfs up. ::) | retired early | investorshub | 12/22/2022 2:35:47 PM |
Chart setup perfectly here -> time is koming | BEIJING BILL | investorshub | 08/17/2022 4:51:49 PM |
Hey whatever it takes to see it rise | retired early | investorshub | 05/27/2022 5:06:22 PM |
,,,,,,,Im out | THEMASTERS_SON | investorshub | 04/04/2022 6:56:50 PM |
3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology | unpathedhaunt | investorshub | 03/22/2022 3:00:14 PM |
KABOOM !! ve got movement!! | BEIJING BILL | investorshub | 03/03/2022 2:24:32 PM |
Looks like word is getting out. :) | retired early | investorshub | 02/25/2022 5:20:13 PM |
I agree. The buy consensus is at 83%.3 | retired early | investorshub | 01/04/2022 7:11:27 PM |
$HUGE insider buy | Nathans123 | investorshub | 01/04/2022 1:14:01 AM |
$OGEN HOD | TheFinalCD | investorshub | 12/20/2021 4:51:16 PM |
lets get this back over $1 | shurtha2000 | investorshub | 12/20/2021 3:50:52 PM |
Oragenics ($OGEN) Extends Collaboration with the National Research | alisher | investorshub | 12/20/2021 1:46:22 PM |
Oragenics Announces Positive COVID-19 Challenge Study Results | alisher | investorshub | 12/04/2021 10:48:57 PM |
News! | Renegade Rich | investorshub | 12/01/2021 4:59:31 PM |
ORAGENICS is really on a good way to | Mountainman5 | investorshub | 09/12/2021 12:27:53 PM |
Opps good call. I own both and posted | retired early | investorshub | 08/30/2021 2:01:26 PM |
How does that help $OGEN? | oakrock | investorshub | 08/26/2021 5:44:18 AM |
Qiagen has received emergency use authorization from the | retired early | investorshub | 08/06/2021 5:28:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated April ...
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has execu...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II ...